Secondary Logo

Institutional members access full text with Ovid®

Share this article on:

ONE-YEAR OUTCOMES OF INTRAVITREAL BEVACIZUMAB (AVASTIN) THERAPY FOR POLYPOIDAL CHOROIDAL VASCULOPATHY

Cheng, Cheng-Kuo MD*†‡; Peng, Chi-Hsien MD*†§; Chang, Chun-Kai MD*; Hu, Chao-Chien MD*†; Chen, Lee-Jen MD

doi: 10.1097/IAE.0b013e3181f84fdf
Original Study

Purpose: To report on 1-year visual, anatomical, and angiographic responses with intravitreal bevacizumab for the treatment of polypoidal choroidal vasculopathy.

Methods: Patients with macula-involved, symptomatic polypoidal choroidal vasculopathy with initial best-corrected visual acuity of 20/400 or better and a minimal follow-up period of 12 months were retrospectively enrolled. Eyes were treated with intravitreal bevacizumab (2.5 mg) at baseline and monitored monthly for best-corrected visual acuity and central retinal thickness (by optical coherence tomography). Indocyanine green angiography was evaluated on a 6-month basis. Eyes were retreated on an “as-needed” basis according to visual and anatomical changes.

Results: A total of 35 eyes of 33 patients were treated with a mean of 3.3 (range, 1-8) times of injection. Best-corrected visual acuity significantly improved from a mean logarithm of the minimum angle of resolution of 0.79 ± 0.42 at baseline (Snellen equivalent, 20/123) to 0.69 ± 0.47 (20/94), 0.66 ± 0.45 (20/87), 0.67 ± 0.44 (20/87), 0.67 ± 0.48 (20/87), and 0.67 ± 0.51 (20/87) at 1, 3, 6, 9, and 12 months, respectively (P = 0.002, 0.0003, 0.0008, 0.017, and 0.02, respectively; paired Student's t-test). Central retinal thickness also significantly improved from a mean of 297 ± 94 μm at baseline to 215 ± 58 μm, 214 ± 59 μm, 218 ± 79 μm, 213 ± 75 μm, and 221 ± 61 μm at 1, 3, 6, 9, and 12 months, respectively (all P < 0.0001, paired Student's t-test). Indocyanine green angiography showed 3 of 32 eyes (9.4%) and 5 of 31 eyes (16.1%) with completely resolved polyps and 11 of 32 eyes (34.4%) and 10 of 31 eyes (32.3%) with reduced polyps at 6 and 12 months, respectively. No systemic complication or severe local complication, such as endophthalmitis, was found.

Conclusion: Intravitreal bevacizumab therapy has a favorable outcome in improving visual acuity and macular exudative changes in patients with polypoidal choroidal vasculopathy. It can also moderately reduce polypoidal lesions on indocyanine green angiography.

Intravitreal bevacizumab therapy has a favorable outcome in improving visual acuity and macular exudative changes in patients with polypoidal choroidal vasculopathy. It can also moderately reduce polypoidal lesions on indocyanine green angiography.

From the *Department of Ophthalmology, Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan; †Department of Ophthalmology, College of Medicine, Fu Jen Catholic University, Taipei, Taiwan; ‡Department of Ophthalmology, College of Medicine, National Taiwan University, Taipei, Taiwan; §Institute of Clinical Medicine, National Yang-Ming University, Taipei, Taiwan; and ¶Department of Ophthalmology, Mackay Memorial Hospital, Taipei, Taiwan.

Supported by the Shin Kong Wu Ho-Su Memorial Hospital (SKH-8302-96-DR-23, SKH-8302-97-DR-26, SKH-8302-98-DR-27, and SKH-8302-99-DR-32), Taipei, Taiwan.

The authors have no proprietary or commercial interests related to this article.

Reprint requests: Cheng-Kuo Cheng, MD, Department of Ophthalmology, Shin Kong Wu Ho-Su Memorial Hospital, No. 95, Wen-Chang Road, Shih-Lin District, Taipei 11120, Taiwan; e-mail: ckcheng.md@yahoo.com.tw

© The Ophthalmic Communications Society, Inc.